Management of Cardiac Failure in the Intensive Care Unit

  • Paul Ellis Marik


Heart failure is a serious condition affecting an estimated 2 million Americans and is a common reason for hospitalization. Patients presenting with an acute deterioration of cardiac function are often admitted to the ICU. These patients are likely to benefit from treatment in an ICU. However, patients with end-stage cardiac failure whose condition has progressed slowly and inexorably despite maximal medical therapy are poor candidates for admission to the ICU, unless they are candidates for cardiac transplantation or have suffered from an acute medical complication. The following patients with cardiac failure may benefit from admission to an ICU:
  • Worsening pulmonary edema with acute respiratory failure

  • Acute myocardial ischemia

  • Acute hemodynamic compromise due to arrhythmias

  • Severe complicating disease, e. g., pneumonia


Heart Failure Chronic Heart Failure Diastolic Dysfunction Cardiac Failure Severe Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  1. 1.
    A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) investigators. N Engl J Med. 1997;337:1576–1583.CrossRefGoogle Scholar
  2. 2.
    CAST investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412.CrossRefGoogle Scholar
  3. 3.
    CIBIS investigators. A randomized trial of beta-blockade in heart failure: The cardiac insufficiency bisoprolol study. Circulation. 1994;90:1765–1773.Google Scholar
  4. 4.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Engl J Med. 1987;316:1429–1435.CrossRefGoogle Scholar
  5. 5.
    Davies SW, Bailey J, Keegan J, et al. Reduced pulmonary microvascular permeability in severe chronic left heart failure. Am Heart J. 1992;124:137–142.PubMedCrossRefGoogle Scholar
  6. 6.
    Dries F, Krell MJ, Whitloe, et al. Intermittent dobutamine in ambulatory patients with chronic heart failure. Circulation. 1986;74(suppl 11):11–38.Google Scholar
  7. 7.
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336 (8):525–533.CrossRefGoogle Scholar
  8. 8.
    Eichhorn EJ. Restoring function in failing hearts: the effects of beta blockers. Am J Med. 1998;104:163–169.PubMedCrossRefGoogle Scholar
  9. 9.
    Galve E, Rius T, Ballester, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–1082.PubMedCrossRefGoogle Scholar
  10. 10.
    Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, Lense L, Wachspress J. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77(3):607–612.PubMedCrossRefGoogle Scholar
  11. 11.
    Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med. 1996;335:1933–1940.PubMedCrossRefGoogle Scholar
  12. 12.
    O’Connor CM, Carson PE, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82(7):881–887.PubMedCrossRefGoogle Scholar
  13. 13.
    Packer M, Bristow MR, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–1355.PubMedCrossRefGoogle Scholar
  14. 14.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawl of digoxin from patients with chronic heart failure treated with angiotensin-converting- enzyme inhibitors. N Engl J Med. 1993;329:1–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEnglJ Med. 1999;341:709–717.CrossRefGoogle Scholar
  16. 16.
    Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255–259.PubMedCrossRefGoogle Scholar
  17. 17.
    Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77–82.PubMedCrossRefGoogle Scholar
  18. 18.
    SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:685–691.CrossRefGoogle Scholar
  19. 19.
    Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation. 1968;37:900–911.PubMedGoogle Scholar
  20. 20.
    Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:2177–2287.CrossRefGoogle Scholar
  21. 21.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of meto- prolol in idiopathic cardiomyopathy. Lancet. 1993;342:1441–1446.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Paul Ellis Marik
    • 1
  1. 1.Critical Care MedicineMercy Hospital of PittsburghPittsburghUSA

Personalised recommendations